MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
Proceeds from exercisedstock options$446K Net cash provided byfinancing activities$446K Net decrease in cashand cash...-$4,941K Canceled cashflow$446K Stock-based compensation$6,243K Accounts receivable, net-$3,948K Accounts payable$3,654K Other current assets-$338K Depreciation andamortization$124K Net cash used inoperating activities-$5,260K Canceled cashflow$14,307K Net cash used ininvesting activities-$127K Net loss-$8,436K Accrued liabilities andother-$4,376K Foreign currencytransactions$2,752K Inventories$2,394K Inventories, long-term$1,451K Other assets$158K Purchase of property andequipment$127K
Cash Flow
source: myfinsight.com

Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics, Inc. (YMAB)